Three months after Mylan NV moved on to Meda AB of Sweden with Cravath, Swaine & Moore in tow, the generic drug giant has again retained the firm to advise on its proposed $1 billion acquisition of the dermatology division of Renaissance Acquisition Holdings LLC, a portfolio company of Lake Forest, Illinois-based private equity firm RoundTable Healthcare Partners LP.
The deal, announced Friday, will see Mylan pay $950 million to RoundTable at closing, and up to $50 million more in contingency payments. Reuters reported that Renaissance, which has 50 products (half in development), generated revenues of $370 million last year.
